Video

Understanding Ketamine's Antidepressant Effect

Author(s):

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.

A new study on ketamine found that increasing dosage was associated with greater antidepressant effects and lower levels of glutamate. The degree of clinical improvement was unrelated to any experienced side effects.

In an interview with HCPLive®, study investigator J. John Mann, MD, Professor of Translational Neuroscience, Columbia University, offered further insight into these exciting findings and discussed its implications on treatment for major depressive disorder.

Mann explained they were primarily interested in understanding glutamate’s role as mediator between ketamine and its effect. Using a PET scan to capture patient glutamate and GABA levels during and after drug infusion, they discovered ketamine attenuated glutamate levels in exact proportion to the dose received.

“Statistically, we were able to show that dose-dependent antidepressant effect of ketamine was largely explained by the effect of the Glx peak in the part of the brain related to depression circuitry.”

He then said that one could theoretically discover other compounds that have a similar effect on glutamate levels. Furthermore, it would be essential to find compounds that lack the side effects typically associated with ketamine.

By having a better understanding of these mechanisms behind ketamine’s antidepressant effect, researchers might be able to predict the antidepressant potential and impact of future drugs relative to ketamine, Mann added.

Related Videos
Parent Stress Reduces Over Time When Weaning Child Off Tube Feeding with Hide Okuno, MS
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Akif Shameem, MD: Generalized Anxiety Disorder Linked to Longer Hospitals in Children with IBD
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.